Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Where's the real news?

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Aug 21, 2024 6:02pm

162 Views

Post# 36190822

RE:RE:RE:RE:RE:RE:RE:RE:Where's the real news?

enriquesuave wrote: Competition is CGON. CG0007. Many more treatments good results, Cannot be used on immune compromised patients( a big chunk). Storage can be an issue. Once they stop treating we don't yet know how fast CR numbers drop long term. Only short term numbers! We are a way better option, but the FDA and med community need many options as no one solution works 100% for all. Perhaps Rutherin come with Ruvidar for hard to treat cases may get us close to 100%?

"Options" being the key word imo. As you stated, current therapies require many more treatments, both induction & ongoing maintenance...the latter potentially being ad infinitum in order to help keep cancer in check, which they often fail to achieve.

Historically, the bottom line problem with the competition is that they "all" simply postpone radical cystectomy rather than provide "longer-term" cancer control, & this postponement is achieved at the expense of patient quality of life (i.e. frequent treatments/trips to the doctor, overall patient satisfaction/functional status & cumulative side effects).

This latest news adds to another & prehaps more important key word, "Versatility". The clinical applications seem to tremendously expand as both a mono & combo/synergistic therapy. To add, literature/experimental data on Ruthenium-based compounds have shown promise in their potential use as complementary anti-diabetic agents...by increasing insulin sensitivity. This is just another appliction that warrants tox/clincial studies.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario